JBC DNA damage antibodies

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M101885200 on April 25, 2001

J. Biol. Chem., Vol. 276, Issue 26, 23572-23580, June 29, 2001
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/26/23572    most recent
M101885200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parada, Y.
Right arrow Articles by Lam, E. W.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parada, Y.
Right arrow Articles by Lam, E. W.-F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

BCR-ABL and Interleukin 3 Promote Haematopoietic Cell Proliferation and Survival through Modulation of Cyclin D2 and p27Kip1 Expression*

Yelena Paradaabc, Lolita Banerjiabc, Janet Glassfordabd, Nicholas C. Leaef, Manuel Colladoa, Carmen Rivasg, John L. Lewisgh, Myrtle Y. Gordongi, N. Shaun B. Thomasej, and Eric W.-F. Lamabk

From the a Ludwig Institute for Cancer Research and Section of Virology and Cell Biology, Imperial College School of Medicine at St Mary's, Norfolk Place, London W2 1PG, United Kingdom, the b CRC Labs and Section of Cancer Cell Biology, Imperial College School of Medicine at Hammersmith Hospital, Du Cane Road, London W12 ONN, United Kingdom, the g LRF Centre for Adult Leukaemia, Department of Haematology, Royal Postgraduate Medical School, Imperial College School of Medicine at Hammersmith's Campus, London W12 0NN, United Kingdom, and the e Department of Haematological Medicine, Guy's, King's, St. Thomas' School of Medicine, Rayne Institute, Leukaemia Sciences, Coldharbour Lane, London SE5 9NU, United Kingdom

Although it is evident that BCR-ABL can rescue cytokine-deprived hematopoietic progenitor cells from cell cycle arrest and apoptosis, the exact mechanism of action of BCR/ABL and interleukin (IL)-3 to promote proliferation and survival has not been established. Using the pro-B cell line BaF3 and a BaF3 cell line stably overexpressing BCR-ABL (BaF3-p210), we investigated the proliferative signals derived from BCR-ABL and IL-3. The results indicate that both IL-3 and BCR-ABL target the expression of cyclin Ds and down-regulation of p27Kip1 to mediate pRB-related pocket protein phosphorylation, E2F activation, and thus S phase progression. These findings were further confirmed in a BaF3 cell line (TonB.210) where the BCR-ABL expression is inducible by doxycyclin and by using the drug STI571 to inactivate BCR-ABL activity in BaF3-p210. To establish the functional significance of cyclin D2 and p27Kip1 expression in response to IL-3 and BCR-ABL expression, we studied the effects of ectopic expression of cyclin D2 and p27Kip1 on cell proliferation and survival. Our results demonstrate that both cyclin D2 and p27Kip1 have a role in BaF3 cell proliferation and survival, as ectopic expression of cyclin D2 is sufficient to abolish the cell cycle arrest and apoptosis induced by IL-3 withdrawal or by BCR-ABL inactivation, while overexpression of p27Kip1 can cause cell cycle arrest and apoptosis in the BaF3 cells. Furthermore, our data also suggest that cyclin D2 functions upstream of p27Kip1, cyclin E, and cyclin D3, and therefore, plays an essential part in integrating the signals from IL-3 and BCR-ABL with the pRB/E2F pathway.

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

c Contributed equally to the results of this study.

d Supported by the Leukemia Research Fund.

f Supported by the Sir Charles Wolfson Trust.

h Supported by the Leukemia Research Fund.

i Supported by the Leukemia Research Fund.

j Supported by the Leukemia Research Fund and the Sir Charles Wolfson Trust.

k Supported by the Leukemia Research Fund. To whom correspondence should be addressed: CRC Labs and Section of Cancer Cell Biology, Imperial College School of Medicine at Hammersmith Hospital, Du Cane Road, London W12 ONN, United Kingdom. Tel.: 44-020-8383-5834; Fax: 44-20-8383-5830; E-mail: eric.lam@ic.ac.uk.

Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
M. Zhang, W. Fu, S. Prabhu, J. C. Moore, J. Ko, J. W. Kim, B. J. Druker, V. Trapp, J. Fruehauf, H. Gram, et al.
Inhibition of Polysome Assembly Enhances Imatinib Activity against Chronic Myelogenous Leukemia and Overcomes Imatinib Resistance
Mol. Cell. Biol., October 15, 2008; 28(20): 6496 - 6509.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Agarwal, T. G. P. Bumm, A. S. Corbin, T. O'Hare, M. Loriaux, J. VanDyke, S. G. Willis, J. Deininger, K. I. Nakayama, B. J. Druker, et al.
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease
Blood, September 1, 2008; 112(5): 1960 - 1970.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X. Mao, S.-b. Liang, R. Hurren, M. Gronda, S. Chow, G. W. Xu, X. Wang, R. B. Zavareh, N. Jamal, H. Messner, et al.
Cyproheptadine displays preclinical activity in myeloma and leukemia
Blood, August 1, 2008; 112(3): 760 - 769.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. G. Harb, B. I. Chyla, and C. S. Huettner
Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis
Blood, April 1, 2008; 111(7): 3760 - 3769.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. Susaki, K. Nakayama, and K. I. Nakayama
Cyclin D2 Translocates p27 out of the Nucleus and Promotes Its Degradation at the G0-G1 Transition
Mol. Cell. Biol., July 1, 2007; 27(13): 4626 - 4640.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
T. E. Bullock, B. Wen, S. B. Marley, and M. Y. Gordon
Potential of CD34 in the Regulation of Symmetrical and Asymmetrical Divisions by Hematopoietic Progenitor Cells
Stem Cells, April 1, 2007; 25(4): 844 - 851.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
K. Wolanin, A. Magalska, G. Mosieniak, R. Klinger, S. McKenna, S. Vejda, E. Sikora, and K. Piwocka
Curcumin Affects Components of the Chromosomal Passenger Complex and Induces Mitotic Catastrophe in Apoptosis-Resistant Bcr-Abl-Expressing Cells
Mol. Cancer Res., July 1, 2006; 4(7): 457 - 469.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. J. Andreu, E. Lledo, E. Poch, C. Ivorra, M. P. Albero, J. A. Martinez-Climent, C. Montiel-Duarte, J. Rifon, J. Perez-Calvo, C. Arbona, et al.
BCR-ABL Induces the Expression of Skp2 through the PI3K Pathway to Promote p27Kip1 Degradation and Proliferation of Chronic Myelogenous Leukemia Cells
Cancer Res., April 15, 2005; 65(8): 3264 - 3272.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. G. Kharas and D. A. Fruman
ABL Oncogenes and Phosphoinositide 3-Kinase: Mechanism of Activation and Downstream Effectors
Cancer Res., March 15, 2005; 65(6): 2047 - 2053.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Tomoda, J.-y. Kato, E. Tatsumi, T. Takahashi, Y. Matsuo, and N. Yoneda-Kato
The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression
Blood, January 15, 2005; 105(2): 775 - 783.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. Fernandez de Mattos, A. Essafi, I. Soeiro, A. M. Pietersen, K. U. Birkenkamp, C. S. Edwards, A. Martino, B. H. Nelson, J. M. Francis, M. C. Jones, et al.
FoxO3a and BCR-ABL Regulate cyclin D2 Transcription through a STAT5/BCL6-Dependent Mechanism
Mol. Cell. Biol., November 15, 2004; 24(22): 10058 - 10071.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Calabretta and D. Perrotti
The biology of CML blast crisis
Blood, June 1, 2004; 103(11): 4010 - 4022.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. Mohamedali, I. Soeiro, N. C. Lea, J. Glassford, L. Banerji, G. J. Mufti, E. W.-F. Lam, and N. S. B. Thomas
Cyclin D2 controls B cell progenitor numbers
J. Leukoc. Biol., December 1, 2003; 74(6): 1139 - 1143.
[Abstract] [Full Text]

Home page
 BloodHome page
T. Grunberger, P. Demin, O. Rounova, N. Sharfe, L. Cimpean, H. Dadi, A. Freywald, Z. Estrov, and C. M. Roifman
Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor
Blood, December 1, 2003; 102(12): 4153 - 4158.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. E. Ouriaghli, E. Sloand, L. Mainwaring, H. Fujiwara, K. Keyvanfar, J. J. Melenhorst, K. Rezvani, G. Sconocchia, S. Solomon, N. Hensel, et al.
Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase
Blood, November 15, 2003; 102(10): 3786 - 3792.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Bouscary, F. Pene, Y.-E. Claessens, O. Muller, S. Chretien, M. Fontenay-Roupie, S. Gisselbrecht, P. Mayeux, and C. Lacombe
Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation
Blood, May 1, 2003; 101(9): 3436 - 3443.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
N. C. Lea, S. J. Orr, K. Stoeber, G. H. Williams, E. W.-F. Lam, M. A. A. Ibrahim, G. J. Mufti, and N. S. B. Thomas
Commitment Point during G0->G1 That Controls Entry into the Cell Cycle
Mol. Cell. Biol., April 1, 2003; 23(7): 2351 - 2361.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Podtcheko, A. Ohtsuru, S. Tsuda, H. Namba, V. Saenko, M. Nakashima, N. Mitsutake, S. Kanda, J. Kurebayashi, and S. Yamashita
The Selective Tyrosine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic Thyroid Cancer Cells
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1889 - 1896.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Spiekermann, R. J. Dirschinger, R. Schwab, K. Bagrintseva, F. Faber, C. Buske, S. Schnittger, L. M. Kelly, D. G. Gilliland, and W. Hiddemann
The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3
Blood, February 15, 2003; 101(4): 1494 - 1504.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Komatsu, T. Watanabe, M. Uchida, M. Mori, K. Kirito, S. Kikuchi, Q. Liu, T. Tauchi, K. Miyazawa, H. Endo, et al.
A Member of Forkhead Transcription Factor FKHRL1 Is a Downstream Effector of STI571-induced Cell Cycle Arrest in BCR-ABL-expressing Cells
J. Biol. Chem., February 14, 2003; 278(8): 6411 - 6419.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. S. Holtz, M. L. Slovak, F. Zhang, C. L. Sawyers, S. J. Forman, and R. Bhatia
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation
Blood, May 15, 2002; 99(10): 3792 - 3800.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.